Your browser doesn't support javascript.
loading
No evidence of QT prolongation with supratherapeutic doses of aleglitazar.
Sturm, Stefan; Bentley, Darren; Jordan, Paul; Russell-Yarde, Fiona; Ruf, Thorsten.
Affiliation
  • Sturm S; F. Hoffmann-La Roche AG, pRED, Pharma Research & Early Development, Basel, Switzerland. stefan.sturm@roche.com
J Cardiovasc Pharmacol ; 59(3): 288-97, 2012 Mar.
Article in En | MEDLINE | ID: mdl-22113345
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oxazoles / Quinolines / Aza Compounds / Thiophenes / Long QT Syndrome Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: J Cardiovasc Pharmacol Year: 2012 Document type: Article Affiliation country: Switzerland Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oxazoles / Quinolines / Aza Compounds / Thiophenes / Long QT Syndrome Type of study: Clinical_trials Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: J Cardiovasc Pharmacol Year: 2012 Document type: Article Affiliation country: Switzerland Country of publication: United States